Skip to content
Clinical Trials – home
Charite Universitaetsmedizin Berlin KöR
Sponsor

Charite Universitaetsmedizin Berlin KöR

Germany Augustenburger Platz 1, Wedding, 13353 Berlin, Germany

About the sponsor

Autoimmune disease research includes ANCA-associated vasculitis, rheumatoid arthritis, axial spondyloarthritis, localized scleroderma, plaque psoriasis, and chronic hand eczema, with additional work in immune-mediated tissue inflammation.

  • ANCA-associated vasculitis
  • Rheumatoid arthritis
  • Psoriasis and eczema
  • Scleroderma and spondyloarthritis

These studies also extend to immune-cell targeted approaches and inflammatory skin and joint conditions.

About Specializations

Charite Universitaetsmedizin Berlin KöR runs clinical trials in conditions such as Colorectal cancer metastatic, Rheumatoid arthritis, Psoriasis, Post-acute COVID-19 syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

27 clinical trials

Comparing Two Treatment Lengths of Cetuximab, Avelumab, Cisplatin, and Docetaxel for Patients with Returning Spread Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Depression

Recruiting

Testing dehydroepiandrosterone combined with standard antidepressants for patients with treatment-resistant depression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lactose Monohydrate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Safety Study of Regulatory T Cells (TREG02) and Tacrolimus Discontinuation in Adult Liver Transplant Recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Safety Study of Regulatory T Cells (TREG02) in Patients After Kidney Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study Comparing Rituximab and KYV-101 for Patients with Active, ACPA-Positive, Treatment-Resistant Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:KYV-101
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Safety and Effectiveness of Abatacept and Daratumumab for Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study Comparing Trifluridine/Tipiracil with Panitumumab or Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iloprost Trometamol
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.